Publications by Professor Ann Daly - ePrints

Browsing publications by Professor Ann Daly.

Newcastle Authors	Title	Year
Professor Fiona Oakley Dr Simon Cockell Dr Olivier Govaere Professor Ann Daly Professor Arun Sanyal et al.	An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)	2024
Dr Olivier Govaere Dr Simon Cockell Michalina Zatorska Kristy Wonders Professor Dina Tiniakos et al.	Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment	2024
Professor Ann Daly	PharmVar GeneFocus: CYP4F2	2024
Professor Ann Daly	Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population	2024
Professor Ann Daly	Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet	2024
Dr Olivier Govaere Dr Megan Hasoon Dr Simon Cockell Dr Dina Tiniakos Professor Ann Daly et al.	A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures	2023
Professor Ann Daly	Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort	2023
Professor Ann Daly	Genetics of drug-induced liver injury: Current knowledge and future prospects	2023
Dr Olivier Govaere Professor Ann Daly	Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate	2023
Professor Ann Daly	Relevance of Pharmacogenomics to the Safe Use of Antimicrobials	2023
Professor Ann Daly	The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress	2023
Dr Rebecca Darlay Professor Heather Cordell Professor Quentin Anstee Professor Ann Daly	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation	2022
Dr Wei-yu Lin Dr Sarah Fordham Dr Nicola Sunter Dr Claire Elstob Dr Yaobo Xu et al.	Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x)	2022
Dr Rebecca Darlay Professor Heather Cordell Professor Ann Daly Professor Chris Day Dr Steven Masson et al.	Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275–282] (Journal of Hepatology (2022) 76(2) (275–282), (S0168827821021115), (10.1016/j.jhep.2021.10.005))	2022
Professor Ann Daly	Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement	2022
Professor Ann Daly	Epigenetics in drug disposition & drug therapy: symposium report of the 24th North American meeting of the International Society for the Study of Xenobiotics (ISSX)	2022
Dr Katherine Johnson Dr Peter Leary Dr Olivier Govaere Dr Matthew Barter Sarah Charlton et al.	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance	2022
Dr Olivier Govaere Dr Rebecca Darlay Dr Julien Peltier Dr Jeremy Palmer Dr Massimo Younes et al.	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease	2022
Dr Olivier Govaere Professor Ann Daly Professor Quentin Anstee	Metabolic signatures across the full spectrum of nonalcoholic fatty liver disease	2022
Professor Ann Daly	Pharmacogenetics of the cytochromes P450: Selected pharmacological and toxicological aspects	2022
Dr Olivier Govaere Professor Ann Daly Professor Quentin Anstee	Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease	2022
Professor Ann Daly	Human Leukocyte Antigen B14:01* and B35:01* Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury	2021
Nardeen Eldafashi Dr Rebecca Darlay Dr Ruchi Shukla Misti McCain Robyn Watson et al.	A pdcd1 role in the genetic predisposition to nafld-hcc?	2021
Professor Ann Daly	Genetic risk factors in drug-induced liver injury due to isoniazid-containing anti-tuberculosis drug regimens	2021
Dr Rebecca Darlay Dr Steven Masson Professor Chris Day Professor Ann Daly Professor Heather Cordell et al.	Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors	2021
Dr Wei-Yu Lin Dr Sarah Fordham Dr Nicola Sunter Dr Claire Elstob Dr Yaobo Xu et al.	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia	2021
Dr Olivier Govaere Dr Dina Tiniakos Professor Pierre Bedossa Dr Simon Cockell Dr Massimo Younes et al.	NASH limits anti-tumor surveillance in immunotherapy-treated HCC	2021
Dr Steven Masson Professor Ann Daly Professor Heather Cordell Professor Chris Day	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers	2021
Professor Ann Daly Dr Olivier Govaere Professor Quentin Anstee	Peptide-Based Urinary Monitoring of Fibrotic Non-Alcoholic Steatohepatitis by Mass Barcoded Activity-Based Sensors	2021
Professor Ann Daly	Pharmacogenomics spotlight commentary: From the United Kingdom to global populations	2021
Professor Quentin Anstee Priyadarshini Basu Dr Pallav Bhatnagar Professor Ann Daly	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis	2021
Dr Olivier Govaere Dr Simon Cockell Professor Ann Daly Professor Quentin Anstee	Transcriptomics Identify Thrombospondin-2 as a Biomarker for Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis	2021
Professor Quentin Anstee Dr Rebecca Darlay Dr Simon Cockell Dr Olivier Govaere Dr Dina Tiniakos et al.	Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically-Characterised Cohort	2020
Professor Ann Daly	HLA associations with infliximab-induced liver injury	2020
Mohammad Alshabeeb Professor Ann Daly	Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav	2020
Professor Ann Daly	Polygenic architecture informs potential vulnerability to drug-induced liver injury	2020
Dr Olivier Govaere Dr Simon Cockell Dr Dina Tiniakos Dr Rachel Queen Dr Massimo Younes et al.	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis	2020
Professor Ann Daly	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury	2019
Dr Tom Chamberlain Dr Sally Coulthard Mohammad Alshabeeb Professor Ann Daly	Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles	2019
Wi Phatvej Dr Harish Datta Dr Simon Wilkinson Dr Elaine Mutch Professor Ann Daly et al.	Endocytosis and lack of cytotoxicity of alkyl–capped silicon quantum dots prepared from porous silicon	2019
Professor Ann Daly	Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants among Patients with NSAID-Induced Liver Injury	2019
Professor Ann Daly	Shared Genetic Risk Factors Across Carbamazepine‐Induced Hypersensitivity Reactions	2019
Dr Steven Masson Professor Ann Daly Professor Heather Cordell Professor Chris Day	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis	2018
Sal Bakar Dr Peter Avery Dr Colin Brown Professor Ann Daly Professor Farhad Kamali et al.	Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case–Control Study	2018
Professor Ann Daly	HLA-A∗33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors	2018
Professor Ann Daly	Human leukocyte antigen (HLA) and other genetic risk factors in drug-induced liver injury (DILI)	2018
Professor Ann Daly	Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: A perspective	2018
Professor Ann Daly	Pharmacogenetics of Adverse Drug Reactions	2018
Professor Ann Daly	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations	2018
Professor Ann Daly	Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury	2017
Dr Sally Coulthard Professor Chris Day Professor Ann Daly	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study	2017
Professor Ann Daly	Defining drug response for stratified medicine	2017
Professor Ann Daly	Drug-Induced cholestasis: Mechanisms and importance	2017
Professor Ann Daly	Drug-Induced Liver Disease	2017
Professor Ann Daly	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor	2017
Professor Ann Daly	Pharmacogenetics: A general review on progress to date	2017
Dr Lucy Walker Professor Ann Daly Dr Luca Miele Professor Quentin Anstee Professor Helen Reeves et al.	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease	2017
Professor Quentin Anstee Dr Yang-Lin Liu Dr Rebecca Darlay Professor Heather Cordell Professor Ann Daly et al.	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans	2017
Professor Ann Daly Professor Farhad Kamali	A multi-factorial analysis of response to warfarin in a UK prospective cohort	2016
Dr Sally Coulthard Professor Ann Daly	HLA-DRB116:01-DQB105:02 is a novel genetic risk factor for flupirtine-induced liver injury	2016
Dr Sally Coulthard Professor Ann Daly	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting	2016
Professor Ann Daly	The Effect of the CYP1A12A* Allele on Colorectal Cancer Susceptibility in a British Population	2016
Professor Ann Daly Professor Chris Day	Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol	2016
Dr Sarah Steven Dr Kieren Hollingsworth Dr Benjamin Aribisala Dr Ahmad Al-Mrabeh Professor Ann Daly et al.	Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes	2016
Professor Chris Day Dr Steven Masson Professor Ann Daly Professor Heather Cordell	Brief Report: Genetics of Alcoholic Cirrhosis-GenomALC Multinational Study	2015
Professor Ann Daly	Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury	2015
Professor Ann Daly	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands	2015
Professor Quentin Anstee Professor Ann Daly Professor Chris Day	Genetics of Alcoholic Liver Disease	2015
Dr Peter Donaldson Professor Ann Daly Dr Luca Ermini Professor Debra Bevitt	Genetics of Complex Disease	2015
Professor Ann Daly	Genome-wide investigation identifies common SNPs on Chr9p22.2 as risk factors for liver injury due to sulfa-methoxazole/trimethoprim	2015
Professor Ann Daly	HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds	2015
Dr Jeremy Palmer Dr Yang-Lin Liu Professor Chris Day Professor Ann Daly Professor Quentin Anstee et al.	Mechanistic Study of TM6SF2 in NAFLD pathogenesis: Stably transfected Huh7 cells over-expressing the TM6SF2 E167K variant exhibit greater levels of oxidative stress	2015
Professor Ann Daly	Minocycline hepatotoxicity: Clinical characterization and identification of HLA- B*35:02 as a risk factor	2015
Professor Farhad Kamali Professor Ann Daly	Oral anticoagulation: a critique of recent advances and controversies	2015
Professor Ann Daly	Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: Review of current knowledge and comparison with selected European populations	2015
Professor Ann Daly Professor Chris Day	PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease	2015
Professor Ann Daly	Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases	2015
Professor Ann Daly	Promiscuous T-cell responses to drugs and drug-haptens	2015
Professor Farhad Kamali Professor Ann Daly	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants	2015
Dr Harsh Sheth Dr Michael Jackson Dr John Tyson Professor Ann Daly Professor Sir John Burn et al.	Relevance of genetic factors to warfarin dosing in India	2015
Rodolphe Anty Professor Chris Day Professor Ann Daly Anh Tran Professor Quentin Anstee et al.	The FNDC5 rs3480 is protective on the steatosis and fibrosis in patients with NAFLD	2015
Professor Ann Daly Professor Chris Day Dr Yang-Lin Liu Professor Quentin Anstee	TM6SF2 as a Genetic Risk Factor for Fibrosis	2015
Dr Yang-Lin Liu Professor Ann Daly Professor Chris Day Professor Quentin Anstee	TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?	2015
Ching Ng Dr Abul Hasnat Professor Chris Day Professor Ann Daly	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group	2014
Dr Yang-Lin Liu Dr Gillian Patman Julian Leathart Professor Alastair Burt Professor Chris Day et al.	Carriage of the PNPLA3 rs738409 C>G Polymorphism Confers an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma	2014
Julian Leathart Professor Ann Daly Professor Chris Day Professor Quentin Anstee	Gene Polymorphisms of Cellular Senescence Marker P21 and Disease Progression in Non-Alcohol-Related Fatty Liver Disease	2014
Professor Ann Daly	Genetic Basis of Drug-Induced Liver Injury: Present and Future	2014
Professor Ann Daly	Human Leukocyte Antigen (HLA) Pharmacogenomic Tests: Potential and Pitfalls	2014
Professor Ann Daly	Is There a Need to Teach Pharmacogenetics?	2014
Professor Ann Daly	Opportunities and limitations: the value of pharmacogenetics in clinical practice	2014
Professor Ann Daly Professor Farhad Kamali	Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy	2014
Professor Ann Daly	Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon	2014
Professor Ann Daly	Pharmacogenomics of Warfarin	2014
Dr Harsh Sheth Dr Matthew Jackson Dr John Tyson Professor Ann Daly Dr Jonathan O'Halloran et al.	Point of care testing for improving risk- benefit ratio of aspirin and warfarin	2014
Dr Yang-Lin Liu Professor Helen Reeves Professor Alastair Burt Dr Dina Tiniakos Professor Stuart McPherson et al.	TM6SF2 rs58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease	2014
Professor Quentin Anstee Dr Rebecca Darlay Julian Leathart Yilei Liu Professor Alastair Burt et al.	A candidate-gene approach to validation of genetic modifier associations using a large cohort with histologically characterised non-alcoholic fatty liver disease	2013
Dr Patrick Kesteven Professor Ann Daly Dr Peter Avery Professor Farhad Kamali	A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study	2013
Dr Patrick Kesteven Julian Leathart Professor Ann Daly Professor Farhad Kamali	A Randomized Trial of Genotype-Guided Dosing of Warfarin	2013
Professor Gareth Veal Julie Errington Sophie Rowbotham Nicola Illingworth Dr Ghada Malik et al.	Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma	2013
Dr Yang-Lin LIU Dr Gillian Patman Julian Leathart Professor Alastair Burt Professor Chris Day et al.	Carriage of PNPLA3 I148M is Associated with an Increased Risk of Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma	2013
Dr Ahmed Elsharkawy Dr Ulrich Schwab Dr Brendan McCarron Professor Alastair Burt Professor Ann Daly et al.	Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser	2013
Professor Ann Daly Professor Chris Day	Genetic Polymorphisms of Galectin-9 (Gal-9) Associated with Risk of Developing Alcoholic Liver Disease (ALD) in Humans	2013
Professor Ann Daly	Human Leukocyte Antigen (HLA)-B(star)57:01-Restricted Activation of Drug-Specific T Cells Provides the Immunological Basis for Flucloxacillin-Induced Liver Injury	2013
Professor Ann Daly	Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population	2013
Professor Quentin Anstee Dr Yang-Lin Liu Professor Heather Cordell Dr Rebecca Darlay Professor Chris Day et al.	Mapping Expression Quantitative Traits Loci (EQTL) for PNPLA3 Gene Identifies Additional SNPs Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) Independent of rs738409	2013
Professor Ann Daly	Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms	2013
Professor Ann Daly	Pharmacogenomics of adverse drug reactions	2013
Professor Ann Daly	Relevance of CYP2E1 to non-alcoholic fatty liver disease	2013
Professor Ann Daly Professor Farhad Kamali	Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs	2012
Professor Ann Daly	CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes	2012
Professor Ann Daly Professor Chris Day	Genetic association studies in drug-induced liver injury	2012
Professor Ann Daly	Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects	2012
Professor Quentin Anstee Dr Rebecca Darlay Julian Leathart Professor Helen Reeves Professor Alastair Burt et al.	Genome-Wide Association Analysis Confirms Importance of PNPLA3 and Identifies Novel Variants Associated With Histologically Progressive Steatohepatitis in NAFLD	2012
Professor Ann Daly	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs	2012
Professor Ann Daly Professor Gareth Veal Dr David Jamieson Dr Sally Coulthard	Pharmacogenomics research at Newcastle University	2012
Ahmad Alserri Professor Quentin Anstee Julian Leathart Julia Patch Professor Chris Day et al.	The SOD2 C₄₇T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies	2012
Dr Ellen Hatch Dr Iain Matthews Professor Ann Daly Professor Farhad Kamali	The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors	2012
Professor Ann Daly	Using genome-wide association studies to identify genes important in serious adverse drug reactions	2012
Dr Tina Biss Dr Peter Avery Julian Leathart Dr John Hanley Professor Ann Daly et al.	VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children	2011
Professor Ann Daly Professor Chris Day	A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease	2011
Professor Ann Daly	Beyond DME: Genetic determinants of drug-induced liver toxicity	2011
Professor Ann Daly	Case Definition and Phenotype Standardization in Drug-Induced Liver Injury	2011
Professor Alan Boddy Professor Ann Daly Professor Gareth Veal	Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases	2011
Dr Shyamal Wahie Professor Ann Daly Professor Heather Cordell Dr Andrew Carmichael Dr Mary Carr et al.	Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study	2011
Dr Gul Ozhan Rajiv Lochan Jayadeva Julian Leathart Richard Charnley Professor Ann Daly et al.	Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility	2011
Rajiv Lochan Jayadeva Professor Ann Daly Professor Helen Reeves Richard Charnley	Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma	2011
Professor Ann Daly Dr Stefano Ballestri Professor Chris Day	Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease	2011
Professor Quentin Anstee Professor Ann Daly Professor Chris Day	Genetic modifiers of non-alcoholic fatty liver disease progression	2011
Professor Quentin Anstee Professor Ann Daly Professor Chris Day	Genetics of alcoholic liver disease and nonalcoholic fatty liver disease	2011
Professor Ann Daly Dr Abul Hasnat	Genotypes and phenotypes of CYP3A in Bangladeshi population	2011
Julian Leathart Professor Ann Daly	Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon(R) probes	2011
Dr Stefano Ballestri Professor Chris Day Professor Ann Daly	Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity	2011
Professor Ann Daly	Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics	2011
Professor Chris Day Dr Peter Donaldson Professor Ann Daly	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and class II alleles	2011
Rajiv Lochan Jayadeva Professor Ann Daly Professor Helen Reeves Richard Charnley	The role of tobacco derived carcinogens in pancreas cancer	2011
Julian Leathart Professor Ann Daly Professor Chris Day	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver	2011
Elise Andrews Professor Matthew Wright Professor Chris Day Professor Ann Daly	A Role for the Pregnane X Receptor in Flucloxacillin-Induced Liver Injury	2010
Professor Ann Daly Professor Farhad Kamali	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives	2010
Dr Kate Potter Professor Heather Cordell Professor Ann Daly Professor Derek Mann Professor John Isaacs et al.	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFĸB signalling pathways	2010
Professor Ann Daly	Drug-induced liver injury: past, present and future	2010
Professor Ann Daly Julian Leathart Professor Alastair Burt Professor Chris Day	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease	2010
Professor Ann Daly	Genome-wide association studies in pharmacogenomics	2010
Ahmad Alserri Professor Ann Daly Professor Chris Day	Homozygosity for the Patatin-Like Phospholipase-3/Adiponutrin I148M Polymorphism Influences Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease	2010
Dr Peter Donaldson Professor Ann Daly Jill Henderson Professor Chris Day	Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury	2010
Dr Fiona Caple Dr Liz Williams Dr Alison Spiers Dr John Tyson Brian Burtle et al.	Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype	2010
Professor Ann Daly Professor Chris Day	Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease	2010
Professor Ann Daly	Pharmacogenetics and human genetic polymorphisms	2010
Professor Ann Daly	Polymorphisms in the Tropomyosin TPM1 Short Isoform Promoter Alter Gene Expression and Are Associated With Increased Risk of Metabolic Syndrome	2010
Professor Ann Daly	Preempting and preventing drug-induced liver injury	2010
Sophie Rowbotham Professor Alan Boddy Dr Chris Redfern Professor Gareth Veal Professor Ann Daly et al.	Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation	2010
Dr Montserrat Briz Del Blanco Dr Katherine Talks Dr John Hanley Dr Patrick Kesteven Professor Ann Daly et al.	Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study	2010
Sophie Rowbotham Professor Ann Daly Professor Gareth Veal Professor Alan Boddy	Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans	2010
Professor Ann Daly Dr Peter Donaldson Dr Pallav Bhatnagar Julia Patch Professor Heather Cordell et al.	HLA-B5701* genotype is a major determinant of drug-induced liver injury due to flucloxacillin	2009
Dr Gary Beale Ahmad Alserri Dr Luca Miele Dr Gillian Patman Professor Ann Daly et al.	Claudin 10 (CLDN10) - a Candidate Suceptibility Gene for NAFLD Progression	2009
Professor Ann Daly	Conference scene: Initiatives of future biobanking in pharmacogenomics	2009
Professor Farhad Kamali Professor Ann Daly	Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data	2009
Professor Farhad Kamali Professor Ann Daly	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study	2009
Professor Ann Daly Professor Chris Day	Genetic Association Studies in Drug-Induced Liver Injury	2009
Professor Farhad Kamali Professor Ann Daly	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design	2009
Dr Katherine Talks Dr John Hanley Dr Patrick Kesteven Dr Peter Avery Professor Ann Daly et al.	Individualised oral vitamin K for reversal of warfarin excessive anticoagulation	2009
Dr John Tyson Dr Fiona Caple Dr Alison Spiers Brian Burtle Professor Ann Daly et al.	Inter-individual variation in nucleotide excision repair in young adults: effects of age, adiposity, micronutrient supplementation and genotype	2009
Professor Ann Daly	Nomenclature for alleles of the cytochrome P450 oxidoreductase gene	2009
Professor Ann Daly	Pharmacogenomics of anticoagulants: Steps toward personal dosage	2009
Ahmad Alserri Professor Ann Daly	PNPLA3 Genotype: Relationship to Severity of Non-Alcoholic Fatty Liver Disease	2009
Dr Stuart Kendrick Julian Leathart Elsbeth Henderson Dr Nimantha De Alwis Dr Stephen Stewart et al.	A 'loss-of-function' mutation in TIRAP, the gene encoding the Toll-like receptor adapter molecule MAL protects against fibrosis in NAFLD but not ALD	2008
Professor Ann Daly	Ann K Daly talks to Tarryn Greenberg, Commissioning Editor	2008
Elise Andrews Professor Ann Daly	Flucloxacillin-induced liver injury	2008
Dr Peter Donaldson Dr Pallav Bhatnagar Julia Patch Jill Henderson Julian Leathart et al.	Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor	2008
Rajiv Lochan Jayadeva Professor Ann Daly Professor Helen Reeves Richard Charnley	Genetic susceptibility in pancreatic ductal adenocarcinoma	2008
Dr Pallav Bhatnagar Professor Chris Day Professor Ann Daly	Genetic variants of hepatic transporters and susceptibility to drug induced liver injury	2008
Professor Ann Daly Professor Gerard Stansby	Increased Platelet-monocyte Aggregation in Male Claudicants with the PlA1/A2 Polymorphism of Gp IIb/IIIa	2008
Professor Ann Daly	Interview	2008
Professor Ann Daly	Pharmacogenomics applications in drug Metabolism: From genotyping to drug label-challenges?	2008
Elise Andrews Professor Matthew Wright Professor Chris Day Professor Ann Daly	Relevance of PXR to Flucloxacillin-induced Liver Injury	2008
Dr Peter Donaldson Dr Pallav Bhatnagar Julia Patch Jill Henderson Julian Leathart et al.	Susceptibility to drug induced liver injury determined by HLA class II genotype	2008
Vasileios Pagmantidis Dr Robert Shiel Professor John Mathers Professor Ann Daly Professor John Hesketh et al.	Evidence that a polymorphism within the 3'UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer	2007
Dr Ruben Thanacoody Professor Ann Daly Dr Joseph Reilly Emeritus Professor Nicol Ferrier Professor Simon Thomas et al.	Factors affecting drug concentrations and QT interval during thioridazine therapy	2007
Dr Nimantha De Alwis Professor Ann Daly Julian Leathart Dr Sushma Saksena Professor Chris Day et al.	Genetic evidence that lipid trafficking plays a key role in fibrosis in non alcoholic fatty liver disease	2007
Professor Ann Daly Julian Leathart Richard Swainsbury Professor Chris Day	Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes	2007
Professor Ann Daly	Individualized drug therapy	2007
Professor Ann Daly	Pharmacogenetics and pharmacogenomics	2007
Professor Ann Daly	Pharmacogenetics of oral anticoagulants	2007
Dr Ellen Hatch Elizabeth Sconce Dr Barry King Dr Hilary Wynne Professor Ann Daly et al.	Polymorphisms in genes associated with the vitamin K epoxide reductase complex do not affect warfarin dose requirement	2007
Professor Ann Daly Ahmad Alserri Julian Leathart Julia Patch Professor Chris Day et al.	The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fibrotic NAFLD: Consistent evidence from case-control and intra-familial allelic association studies	2007
Dr Elaine Mutch Professor Ann Daly Professor Faith Williams	The Relationship between PON1 Phenotype and PON1-192 Genotype in Detoxification of Three Oxons by Human Liver	2007
Dr Ellen Hatch Elizabeth Sconce Professor Ann Daly Professor Farhad Kamali	A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene	2006
Elizabeth Sconce Professor Ann Daly Dr Tayyaba Khan Dr Hilary Wynne Professor Farhad Kamali et al.	APOE genotype makes a small contribution to warfarin dose requirements	2006
Elizabeth Sconce Dr Tayyaba Khan Professor Ann Daly Dr Hilary Wynne Professor Farhad Kamali et al.	Apolipoprotein E polymorphisms do not make a clinically significant contribution to warfarin dose requirements	2006
Professor Ann Daly	Association study of the BDNF Val66Met polymorphism with tardive dyskinesia	2006
Professor Ann Daly Dr Barry King	Contribution of CYP2C9 to variability in vitamin K antagonist metabolism	2006
Dr Ruben Thanacoody Professor Ann Daly Dr Joseph Reilly Emeritus Professor Nicol Ferrier Professor Simon Thomas et al.	Effects of CYP2D6 genotype on QTc interval in recipients of thioridazine	2006
Professor Chris Day Julian Leathart Professor Ann Daly	Genetic evidence for a role for gut flora in the pathogenesis of NASH in humans	2006
Dr Ruben Thanacoody Professor Ann Daly Dr Joseph Reilly Emeritus Professor Nicol Ferrier Professor Simon Thomas et al.	Genetic factors influencing steady-state plasma concentrations of thioridazine and its metabolites	2006
Professor Ann Daly Dr Barry King Julian Leathart	Genotyping for cytochrome P450 polymorphisms	2006
Professor Ann Daly	Significance of the minor cytochrome P450 3A isoforms	2006
Elizabeth Sconce Dr Tayyaba Khan Professor Ann Daly Dr Hilary Wynne Professor Farhad Kamali et al.	Simvastatin results in a lower warfarin dose requirement due to a reduced clearance of warfarin	2006
Elizabeth Sconce Dr Tayyaba Khan Professor Ann Daly Dr Hilary Wynne Professor Farhad Kamali et al.	The impact of simvastatin on warfarin disposition and dose requirements	2006
Dr Barry King Dr Tayyaba Khan Professor Farhad Kamali Professor Ann Daly	[abstract] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism	2005
Elizabeth Sconce Dr Tayyaba Khan Dr Hilary Wynne Dr Patrick Kesteven Dr Peter Avery et al.	[abstract] Pfizer poster communication prize - The influence of patient age, CYP2C9 genotype and height on warfarin dose requirements	2005
Dr Ruben Thanacoody Professor Ann Daly Dr Joseph Reilly Emeritus Professor Nicol Ferrier Professor Simon Thomas et al.	Factors affecting steady-state plasma concentrations of thioridazine and its metabolites and electrocardiographic parameters of cardiac repolarisation in patients on chronic thioridazine therapy	2005
Emerita Professor Suzanne Cholerton Professor Ann Daly	Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility	2005
Dr Catherine Todhunter Dr Alison Sutherland Dr Peter Donaldson Professor Ann Daly Emeritus Professor Roger Francis et al.	Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease	2005
Julian Leathart Professor Ann Daly	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics	2005
Ela Kadioglu Professor Ann Daly	Ser326cys polymorphism in hOGG1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma	2005
Elizabeth Sconce Dr Tayyaba Khan Dr Hilary Wynne Dr Peter Avery Dr Barry King et al.	The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen	2005
Professor Ann Daly	[abstract] Contribution of polymorphisms in xenobiotic metabolism and DNA repair genes to DNA damage and cancer	2004
Vanessa Gage Professor Peter Blain Julian Leathart Professor Ann Daly Professor Faith Williams et al.	Association of DNA damage to human peripheral lymphocytes with age and MnSOD and OGG1 genotype	2004
Professor Ann Daly	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls	2004
Professor Farhad Kamali Dr Tayyaba Khan Dr Barry King Dr Patrick Kesteven Peter Wood et al.	Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin	2004
Professor Ann Daly	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation	2004
Professor Ann Daly Dr Barry King	CYP3A5 phenotype-genotype correlations in a British population - Response	2004
Professor Ann Daly	Development of analytical technology in pharmacogenetic research	2004
Professor Chris Day Professor Ann Daly	Genetic susceptibility to alcoholic liver disease	2004
Professor Ann Daly Dr Barry King	Genotyping of the A6986G polymorphism of CYP3A5	2004
Professor Ann Daly Julian Leathart Professor Chris Day	Hepatic Adducts, Circulating Antibodies, and Cytokine Polymorphisms in Patients with Diclofenac Hepatotoxicity	2004
Emerita Professor Suzanne Cholerton Professor Ann Daly	N-Acetyltransferase (NAT2) Polymorphism and Breast Cancer Susceptibility: A Lack of Association in a Case-Control Study of Turkish Population	2004
Professor Ann Daly	Pharmacogenetics of the cytochromes P450	2004
Professor Ann Daly Dr George Rylance	Protein substitutes for PKU: What's new?	2004
Emma Davis Vanessa Gage Professor Ann Daly Professor Faith Williams	The contribution of genotype to DNA damage in lymphocytes from healthy volunteers	2004
Professor Farhad Kamali Dr Tayyaba Khan Dr Barry King Professor Ann Daly Dr Hilary Wynne et al.	The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements	2004
Dr Barry King Dr Tayyaba Khan Professor Farhad Kamali Professor Ann Daly	Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism	2004
Professor Ann Daly Dr Santosh Gupta	Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication	2004
Professor Ann Daly Julian Leathart Professor Chris Day	A "loss-of-function" polymorphism in ICAM-1 protects heavy drinkers from alcoholic liver disease	2003
Dr Stuart Dunn Professor Ann Daly Dr Trevor Thomas	Altered tropomyosin expression in essential hypertension	2003
Professor Ann Daly	Candidate gene case-control studies	2003
Dr Barry King Julian Leathart Dr Elaine Mutch Professor Faith Williams Professor Ann Daly et al.	CYP3A5 phenotype-genotype correlations in a British population	2003
Professor Ann Daly	Cytochrome P450 polymorphisms and the individualization of drug treatment	2003
Dr Elaine Mutch Professor Ann Daly Julian Leathart Professor Peter Blain Professor Faith Williams et al.	Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?	2003
Professor Ann Daly Julian Leathart Dr Beate Haugk Professor David Jones Professor Alastair Burt et al.	Evidence that alcoholic liver disease is due to immune mechanisms in genetically susceptible drinkers	2003
Dr Stephen Stewart Professor Ann Daly Professor David Jones Julian Leathart Professor Chris Day et al.	Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease	2003
Dr Sushma Saksena Julian Leathart Professor Alastair Burt Emeritus Professor Oliver James Professor Ann Daly et al.	Genetic evidence supporting the two-hit model of NASH pathogenesis	2003
Professor Ann Daly	Genetic Regulation of Warfarin Metabolism and Response	2003
Professor Ann Daly	Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients	2003
Dr Ruben Thanacoody Professor Ann Daly Professor Simon Thomas	Influence of CYP2D6 and CYP2C19 genotypes on the QTc intervals of psychiatric patients taking thioridazine	2003
Dr Ruben Thanacoody Professor Ann Daly Professor Simon Thomas	Influence of CYP2D6 genotype on the QTc interval and plasma concentration of thioridazine and its metabolites of psychiatric patients taking chronic therapy.	2003
Dr Sushma Saksena Julian Leathart Professor Ann Daly Professor Chris Day	Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease	2003
Dr Barry King Dr Tayyaba Khan Professor Farhad Kamali Professor Ann Daly	Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements	2003
Alison Sutherland-Craggs Dr John Mansfield Dr Peter Donaldson Professor Ann Daly Dr Nicholas Thompson et al.	Osteoporosis in Crohn's disease is not determined by vitamin D receptor and interleukin-6 genotype	2003
Professor Ann Daly Dr Barry King	Pharmacogenetics of oral anticoagulants	2003
Professor Ann Daly	Pharmacogenetics of the major polymorphic metabolizing enzymes	2003
Julian Leathart Professor Ann Daly	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide	2003
Julian Leathart Professor Chris Day Professor Ann Daly	Relationship of UGT2B7 genotype with diclofenac hepatotoxicity	2003
Dr Elaine Mutch Dr Lindsey Ferrie Christopher Pedder Professor Faith Williams Professor Ann Daly et al.	The role of metabolism in determining the genotoxicity of organophosphate pesticides	2003
Professor Farhad Kamali Professor Ann Daly Dr Hilary Wynne	Warfarin sensitivity: Be aware of genetic influence	2003
Julian Leathart Professor Chris Day Professor Ann Daly	Association of udp-glucuronosyltransferase (UGT) 2B7 genotype with diclofenac-induced hepatotoxicity	2002
Professor Ann Daly	Common allelic variants of cytochrome P4503A4 and their prevalence in different populations	2002
Dr Namrata Bahadur Julian Leathart Dr Elaine Mutch Dr Stuart Dunn Professor Faith Williams et al.	CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes	2002
Professor Ann Daly Professor Chris Day	CYP2C9 polymorphism and warfarin dose requirements	2002
Professor Ann Daly	CYP2D6 deficiency, a factor in ecstasy related deaths?	2002
Emerita Professor Suzanne Cholerton Professor Ann Daly	Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population	2002
Professor Ann Daly Julian Leathart Dr Beate Haugk Professor David Jones Professor Alastair Burt et al.	Evidence that alcoholic liver disease is due to immune mechanisms in genetically susceptible drinkers	2002
Professor Chris Day Dr Sushma Saksena Julian Leathart Professor Alastair Burt Emeritus Professor Oliver James et al.	Genetic evidence supporting the two-hit model of NASH pathogenesis	2002
Professor Chris Day Julian Leathart Professor Ann Daly	Genetic evidence that fatty liver is involved in the pathogenesis of advanced alcoholic liver disease	2002
Professor Ann Daly	Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk	2002
Alison Sutherland-Craggs Dr John Mansfield Dr Mark Hudson Professor Ann Daly Emeritus Professor Roger Francis et al.	Osteoporosis in Crohn's disease is not determined by NOD2 genotype [abstract]	2002
Professor Ann Daly Emeritus Professor Nicol Ferrier	Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism	2002
Professor Ann Daly Professor Chris Day Dr Peter Donaldson	Polymorphisms in immunoregulatory genes: towards individualised immunosupressive therapy?	2002
Ragen Pfeiffer Professor Ann Daly	Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: A HuGE review	2002
Dr Stephen Stewart Julian Leathart Professor Ann Daly Professor Chris Day	Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis	2002
Dr Stephen Stewart Professor Ann Daly Julian Leathart Professor David Jones Professor Chris Day et al.	A polymorphism in CTLA-4 is associated with the presence of anti-CYP2E1 antibody titres in patients with alcoholic liver disease	2001
Professor Chris Day Julian Leathart Professor Ann Daly Dr Mark Hudson	Association of a 5'-flanking region polymorphism in the interleukin-4 gene with Crohn’s disease in a British population.	2001
Professor Chris Day Julian Leathart Professor Ann Daly Dr Mark Hudson	Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population	2001
Professor Ann Daly Professor Chris Day	Candidate gene case-control association studies: advantages and potential pitfalls	2001
Professor Ann Daly	Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: A pooled analysis of genotype-based studies	2001
Dr Mark Welfare Professor Ann Daly	Genotype for CYP1A2 and Ah receptor and risk of colorectal cancer in north east England	2001
Professor Ann Daly	Human cytochrome P-450 (CYP) genes: A web page for the nomenclature of alleles	2001
Professor Ann Daly	Metabolic gene polymorphism frequencies in control populations	2001
Professor Ann Daly Dr Andrew Hall	Pharmacogenetics of cytotoxic drugs	2001
Professor Ann Daly	Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?	2001
Dr Kaushik Agarwal Professor Ann Daly Julian Leathart Dr Mark Hudson Professor Chris Day et al.	Polymorphisms of immunoregulatory genes: A step towards individually tailored immunosuppression?	2001
Emma Davis Professor Ann Daly Professor Faith Williams	Quantitation of in vitro DNA damage using the comet assay	2001
Dr Andrew Harbottle Professor Ann Daly Dr Kathryn Atherton Professor Frederick Campbell	Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance	2001
Dr Alison Sutherland Professor Chris Day Dr Mark Welfare Professor Ann Daly Dr John Mansfield et al.	Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease	2001
Professor Ann Daly	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression	2001
Professor Chris Day Professor Ann Daly	The genetic basis for non-alcoholic and alcoholic steatohepatitis.	2001
Professor Ann Daly	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants	2001
Professor David Jones Professor Ann Daly Emeritus Professor Oliver James Dr Bijayeswar Vaidya Professor Simon Pearce et al.	CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis	2000
Professor Gary Ford Professor Ann Daly	CYP2D6 and CYP2C19 genotypes of patients with terodilin cardiotoxicity identified through the yellow card system	2000
Professor Gary Ford Professor Ann Daly	CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system	2000
Professor Ann Daly Emeritus Professor Nicol Ferrier	Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients	2000
Professor Ann Daly	Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles	2000
Professor Ann Daly	Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation	2000
Professor Ann Daly Professor Margaret Bassendine Professor Chris Day	Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease	2000
Joanne Smart Professor Ann Daly	Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County	2000
Sandra Campbell Dr Steven Laval Professor Ann Daly	Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis	2000
Professor Chris Day Julian Leathart Professor Ann Daly	Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis	2000
Dr Mark Welfare Professor Margaret Bassendine Professor Ann Daly	The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects	2000
Joanne Smart Professor Ann Daly	Variation in induced CYP1A1 levels: Relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms	2000
Professor Chris Day Dr Patrick Kesteven Professor Ann Daly	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications	1999
Dr Kaushik Agarwal Professor David Jones Professor Ann Daly Professor Margaret Bassendine	CTLA-4 gene polymorphism and chronicity in viral hepatitis	1999
Dr Kaushik Agarwal Professor David Jones Professor Ann Daly Professor Margaret Bassendine Dr Mark Hudson et al.	CTLA-4 gene polymorphism and susceptibility to inflammatory bowel disease (IBD)	1999
Emeritus Professor Robert Perry Professor Ian McKeith Dr Andrew Fairbairn Professor Jim Edwardson Professor Ann Daly et al.	CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease	1999
Dr Mark Welfare Emeritus Professor Murray Aitkin Professor Margaret Bassendine Professor Ann Daly	Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: Lack of a polymorphism in CYP1A2 in Caucasians	1999
Professor Ann Daly	Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues	1999
Professor Ann Daly	Genetic variation of CYP2A6, smoking, and risk of cancer	1999
Professor Ann Daly Dr Mark Welfare	Genotype for codon 105 polymorphism of GSTP1 does not predict susceptibility to UC	1999
Professor Ann Daly Dr Mark Welfare	GSTP1 is not a susceptibility gene for UC	1999
Professor Ann Daly	Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method	1999
Professor Margaret Bassendine Professor Ann Daly	Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer	1999
Mike Cole Emerita Professor Suzanne Cholerton Professor Ann Daly Professor Andrew Pearson Professor Alan Boddy et al.	The effect of fluconazole on cyclophosphamide metabolism in children	1999
Professor David Jones Emerita Professor Julia Newton Professor Ann Daly Professor Chris Day Emeritus Professor Oliver James et al.	Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis	1999
Professor Chris Day Dr Patrick Kesteven Professor Ann Daly	Warfarin dose requirement and CYP2C9 polymorphisms - Reply	1999
Professor Ann Daly Professor Margaret Bassendine Emeritus Professor Oliver James Professor Chris Day	The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: Effect on age of presentation and dependence on alcohol dehydrogenase genotype	1998
Professor Ann Daly	Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County	1996
Professor Alan Boddy Emerita Professor Suzanne Cholerton Professor Ann Daly Professor Andrew Pearson	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide	1994
Professor Alan Boddy Emerita Professor Suzanne Cholerton Professor Ann Daly Professor Janice Ellis Julian Leathart et al.	The pharmacogenetics of chemical carcinogenesis	1992
Dr Chris Redfern Professor Ann Daly	Cellular retinoic acid-binding protein from neonatal rat skin: Purification and analysis	1990
Professor Ann Daly Dr Chris Redfern	Identification and analysis of retinoic acid-binding proteins and receptors from nuclei of mammalican cells	1990
Dr Chris Redfern Professor Ann Daly Carole Todd	The biological activity of retinoids in melanoma cells: Induction of expression of retinoic acid receptor-β by retinoic acid in S91 melanoma cells	1990
Professor Jonathan Rees Professor Ann Daly Dr Chris Redfern	Differential expression of the alpha and beta retinoic acid receptors in tissues of the rat	1989
Professor Ann Daly Professor Jonathan Rees Dr Chris Redfern	Nuclear retinoic acid binding proteins and receptors in retinoic acid responsive cell lines	1989
Professor Ann Daly Dr Chris Redfern	Retinoic acid receptor expression in some retinoic acid responsive cell-lines	1989
Professor Ann Daly Dr Chris Redfern	Purification and properties of cellular retinois acid-binding protein from neonatal rat skin	1988
Professor Ann Daly Dr Chris Redfern	Characterisation of a retinoic-acid-binding component from F9 embryonal-carcinoma-cell nuclei	1987
Professor Ann Daly Dr Chris Redfern	The binding of retinoic acid to nuclei and nuclear subfractions	1985